Scandion Oncology has received approval to initiate part 3 of its Phase II CORIST trial investigating SCO-101 for the treatment of metastatic colorectal cancer (mCRC). Part 3 is an expansion of the trial to evaluate the efficacy of SCO-101 in combination with FOLFIRI in both wild-type RAS (wtRAS) and mutant-RAS patient populations. Part 2 of the trial, which is ongoing, is evaluating wtRAS patients only. With c 44% of mCRC patients possessing the RAS mutation, we believe the pursuit of this new ....
22 Aug 2022
Scandion Oncology - Approval for CORIST part 3
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Scandion Oncology - Approval for CORIST part 3
- Published:
22 Aug 2022 -
Author:
Soo Romanoff -
Pages:
2
Scandion Oncology has received approval to initiate part 3 of its Phase II CORIST trial investigating SCO-101 for the treatment of metastatic colorectal cancer (mCRC). Part 3 is an expansion of the trial to evaluate the efficacy of SCO-101 in combination with FOLFIRI in both wild-type RAS (wtRAS) and mutant-RAS patient populations. Part 2 of the trial, which is ongoing, is evaluating wtRAS patients only. With c 44% of mCRC patients possessing the RAS mutation, we believe the pursuit of this new ....